OmniSonics secures $26 million to further develop OmniWave:
This article was originally published in Clinica
OmniSonics has raised $26m through third round financing to further develop its OmniWave technology platform. OmniWave, a technology that enables the delivery of acoustic energy over the active length of a small diameter wire in an occluded blood vessel, became available on the European market earlier this year and the Wilmington, Massachusetts-based company now has its sights set on the US. The technology's pre-clinical coronary data were presented at last month's Transcatheter Cardiovascular Therapeutics (TCT) meeting and the company's confidence in OmniWave's future is strong. President and CEO Robert Rabiner said that raising the finance "speaks to the promise" of the technology, and is looking forward to "advancing the product within multiple areas of the cardiovascular field". The financing is being led by new investor General Electric Pension Trust.